No Data
No Data
JILIN CHANGLONG: Interim Report 2024
Express News | Jilin Province Huinan Changlong Bio-Pharmacy - Hy Turnover RMB393.1 Mln
Express News | Jilin Province Huinan Changlong Bio-Pharmacy - Hy Profit Attributable RMB104.3 Mln
JILIN CHANGLONG: INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2024
Tracking of Hong Kong stock concepts | The Medical Insurance Bureau has announced the new medical insurance catalog. Institutions believe that the golden opportunity to increase the allocation of the pharmaceutical sector has already opened (including con
The National Medical Insurance Bureau has conducted preliminary reviews on 440 pharmaceuticals for this year's medical insurance catalog, which is an increase from last year.
CICC: The pharmaceutical sector has entered a value investment range, focusing on the domestic innovative drug industry chain and going overseas.
China International Capital Corporation released a research report stating that after three years of systematic adjustment, the pharmaceutical sector has entered the range of value investment.
No Data